Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in a number of its board meetings has had the matter about a name change delved into in a great way. This is still on the weighing balance and eyes are wide open to see what actually happens. The company’s chief executive Joseph Papa while making a statement outlined that […]
